Shares of Arena Pharmaceuticals (ARNA -6.8%) dip on disappointing Belviq script data. According...

Shares of Arena Pharmaceuticals (ARNA -6.8%) dip on disappointing Belviq script data. According to TheStreet's Adam Feuerstein, Belviq TRx for week of June 21st were just 1,829, citing IMS. For the week of June 14th they were 1,087.
From other sites
Comments (19)
  • user418
    , contributor
    Comments (264) | Send Message
    Whats wrong with 80% increase?????
    28 Jun 2013, 12:01 PM Reply Like
  • puppy
    , contributor
    Comments (23) | Send Message
    1,829 scripts for the first full week of sales is a GREAT number. The Eisai Reps started updating doctors on June 7. Prior to that they were not allowed to talk about Belviq. In my opinion AF has been sour on ARNA and Belviq since he predicted that the FDA would not approve Belviq. He was obviously wrong then and the market acceptance is proving to be excellent so far. AF has a lot of Crow on his plate. IMHO
    28 Jun 2013, 12:10 PM Reply Like
  • arbo99
    , contributor
    Comments (16) | Send Message
    Who made the assumption that an 80% increase in scripts is disappointing. Adam is a nobody and if the street accepts his word then SHAME ON THEM. Why is he not reporting VVUS numbers? Oh they were horrible and he doesn't want to come out and say so. So who is he covering for. It looks to me as though he had fun stacking the cards against ARNA. This may be why some people call you Fraudstein Adam. Put both on a level playing field or go under a rock till you learn how to become fair. You hide behind telling everyone you are a ARNA long yet every time you write something it is always slanted to the negative for Arena. You have exposed yourself and most of the investment community on both sides are laughing at you and not with you.
    28 Jun 2013, 12:15 PM Reply Like
  • julian1401
    , contributor
    Comments (85) | Send Message
    thats a 60% increase, which company wouldnt want a 60% increase in sales in its second week? "disappointing" is relative. its waaaay better than Qysmia's launch. this is an overreaction and that blogger does not like Arena from morning
    28 Jun 2013, 12:30 PM Reply Like
  • nandito2010
    , contributor
    Comments (2) | Send Message
    What's wrong with 80% increase after 1st week ???
    28 Jun 2013, 12:31 PM Reply Like
  • eviljoe35
    , contributor
    Comments (83) | Send Message
    wow this article is a total lie. numbers went up 80 percent. who are you kidding? forwarded to SEC
    28 Jun 2013, 12:34 PM Reply Like
  • Mark Broer
    , contributor
    Comments (59) | Send Message
    In case other readers are unaware, ARNA shareholders have filed suit against Adam Feuerstein in an attempt to stop his shenanigans. Information on the suit can be found here:

    28 Jun 2013, 01:09 PM Reply Like
  • Arbitrator
    , contributor
    Comment (1) | Send Message
    Mark, The link you provided has documents that address issues that are all pre-litigation. Please provide detail regarding the law suit and its current status in the Court system..
    29 Jun 2013, 06:20 AM Reply Like
  • wagganer
    , contributor
    Comments (2) | Send Message
    Absolutely ridiculous slant by this so-called analyst. And of course the stock needs just a tiny excuse to go way down. Great news barely budges it up. That is cool. I am here for the long term and from what I can see, the stock is going to grow.
    28 Jun 2013, 02:36 PM Reply Like
  • Iqbal1
    , contributor
    Comments (54) | Send Message
    Gents sorry being ignorant but is this guy write article is some ho supporting Shorts or what ?
    28 Jun 2013, 02:37 PM Reply Like
  • mswee95135
    , contributor
    Comment (1) | Send Message
    I was one of the first 1000. In 14 days I've lost 10 pounds with no side effects. I am 59 and have been overweight all of my life. I am a believer.
    28 Jun 2013, 02:37 PM Reply Like
  • raclay
    , contributor
    Comments (10) | Send Message
    The late action (selloff) coincided with the rebalancing and possibly the last bit of portfolio (un)dressing. Thank you, Adam for the buying opportunity. I recognize that you have some sort of ax to grind, Be careful not to cut yourself with it.
    28 Jun 2013, 04:40 PM Reply Like
  • steinbeck
    , contributor
    Comments (80) | Send Message
    Longs can whine all they want but fact is Arena has underperformed since approval (of course all longs have a cost basis of sub $2) and even sales of $150 million don't support a 2 billion market.
    28 Jun 2013, 10:21 PM Reply Like
  • rbcorral11
    , contributor
    Comments (2) | Send Message
    Thanks Mark
    29 Jun 2013, 06:03 AM Reply Like
  • Mojomagic
    , contributor
    Comments (143) | Send Message
    This AF is sickening. Sales are great, it's too bad Arena is on wrong side of WS, any other stock would have sored. We Arena longs will have our day...many of them, in fact I'm ordering a 2014 Corevtte just to celebrate Aren's success.
    29 Jun 2013, 06:16 AM Reply Like
  • eviljoe35
    , contributor
    Comments (83) | Send Message
    fraudstein also said that DVAX would get approved by FDA, this guy is a shill who helps corrupt funds manipulate PPS of stocks
    29 Jun 2013, 11:14 AM Reply Like
  • Joshua Anderson
    , contributor
    Comments (72) | Send Message
    While it may look impressive on the surface that scripts increased from 1,087 in the first week to 1,829 in the second week, you have to also take into account that since the drug was launched on June 11th, it was only available for four days in the first week (June 11 to June 14) while the script data includes all seven days for the second week (June 15 to June 21). So, while an increase to 1,829 from 1,087 is actually a 68% increase (not 80% or 60%), that increase is all due to the extra number of days that the drug was available in the second week. To compare week 1 with week 2, you have to look at this is on a per day basis. For the first week: 1,087 scripts divided by four days equals 272 scripts per day. For the second week: 1829 scripts divided by seven days equals 261 scripts per day which isn't an increase at all, but rather a decrease of 4% on a per day basis. This is likely too small of a difference to be statistically significant, so I'll be generous and call it a wash, but basically there was no growth between week 1 and week 2. I do expect that script numbers for Belviq should grow, but make no mistake, they are definitely NOT growing a 60-80% per week. I expect more modest growth along the lines of what is being seen for Qsymia so far.
    30 Jun 2013, 04:48 PM Reply Like
  • listech
    , contributor
    Comments (19) | Send Message
    Adam, you dope! At least give a plausible rationale for your stupid comments!
    1 Jul 2013, 10:46 AM Reply Like
  • glssmrbl
    , contributor
    Comments (1312) | Send Message
    Is anyone worried that Belviq is recommended only as a last-resort drug?
    7 Jul 2013, 02:32 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs